338 related articles for article (PubMed ID: 31025257)
21. Anti-tumor effects of a 'human & mouse cross-reactive' anti-ADAM17 antibody in a pancreatic cancer model in vivo.
Ye J; Yuen SM; Murphy G; Xie R; Kwok HF
Eur J Pharm Sci; 2017 Dec; 110():62-69. PubMed ID: 28554668
[TBL] [Abstract][Full Text] [Related]
22. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
23. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
[TBL] [Abstract][Full Text] [Related]
24. Curcumin attenuates hyperglycemia-driven EGF-induced invasive and migratory abilities of pancreatic cancer via suppression of the ERK and AKT pathways.
Li W; Wang Z; Xiao X; Han L; Wu Z; Ma Q; Cao L
Oncol Rep; 2019 Jan; 41(1):650-658. PubMed ID: 30542713
[TBL] [Abstract][Full Text] [Related]
25. LRG-1 promotes pancreatic cancer growth and metastasis via modulation of the EGFR/p38 signaling.
Xie ZB; Zhang YF; Jin C; Mao YS; Fu DL
J Exp Clin Cancer Res; 2019 Feb; 38(1):75. PubMed ID: 30760292
[TBL] [Abstract][Full Text] [Related]
26. CCL18 promotes epithelial-mesenchymal transition, invasion and migration of pancreatic cancer cells in pancreatic ductal adenocarcinoma.
Meng F; Li W; Li C; Gao Z; Guo K; Song S
Int J Oncol; 2015 Mar; 46(3):1109-20. PubMed ID: 25502147
[TBL] [Abstract][Full Text] [Related]
27. Pre-clinical characterization of Dacomitinib (PF-00299804), an irreversible pan-ErbB inhibitor, combined with ionizing radiation for head and neck squamous cell carcinoma.
Williams JP; Kim I; Ito E; Shi W; Yue S; Siu LL; Waldron J; O'Sullivan B; Yip KW; Liu FF
PLoS One; 2014; 9(5):e98557. PubMed ID: 24853121
[TBL] [Abstract][Full Text] [Related]
28. Loss of N-acetylgalactosaminyltransferase 3 in poorly differentiated pancreatic cancer: augmented aggressiveness and aberrant ErbB family glycosylation.
Chugh S; Meza J; Sheinin YM; Ponnusamy MP; Batra SK
Br J Cancer; 2016 Jun; 114(12):1376-86. PubMed ID: 27187683
[TBL] [Abstract][Full Text] [Related]
29. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
[TBL] [Abstract][Full Text] [Related]
30. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
31. RACK1 overexpression associates with pancreatic ductal adenocarcinoma growth and poor prognosis.
Li X; Xiao Y; Fan S; Xiao M; Wang X; Chen X; Li C; Zong G; Zhou G; Wan C
Exp Mol Pathol; 2016 Oct; 101(2):176-186. PubMed ID: 27498047
[TBL] [Abstract][Full Text] [Related]
32. Tsoong induces apoptosis and inhibits proliferation, migration and invasion of pancreatic ductal adenocarcinoma cells.
Luan YP; Li QF; Wu SG; Mao DC; Deng YY; Chen RW
Mol Med Rep; 2018 Mar; 17(3):3527-3536. PubMed ID: 29286105
[TBL] [Abstract][Full Text] [Related]
33. Induction of cell death in pancreatic ductal adenocarcinoma by indirubin 3'-oxime and 5-methoxyindirubin 3'-oxime in vitro and in vivo.
Sano M; Ichimaru Y; Kurita M; Hayashi E; Homma T; Saito H; Masuda S; Nemoto N; Hemmi A; Suzuki T; Miyairi S; Hao H
Cancer Lett; 2017 Jul; 397():72-82. PubMed ID: 28347789
[TBL] [Abstract][Full Text] [Related]
34. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma.
Soltek S; Karakhanova S; Golovastova M; D'Haese JG; Serba S; Nachtigall I; Philippov PP; Werner J; Bazhin AV
Naunyn Schmiedebergs Arch Pharmacol; 2015 Nov; 388(11):1121-8. PubMed ID: 26105003
[TBL] [Abstract][Full Text] [Related]
36. UBL4A inhibits autophagy-mediated proliferation and metastasis of pancreatic ductal adenocarcinoma via targeting LAMP1.
Chen H; Li L; Hu J; Zhao Z; Ji L; Cheng C; Zhang G; Zhang T; Li Y; Chen H; Pan S; Sun B
J Exp Clin Cancer Res; 2019 Jul; 38(1):297. PubMed ID: 31288830
[TBL] [Abstract][Full Text] [Related]
37. Dacomitinib, a new pan-EGFR inhibitor, is effective in killing ovarian cancer cells.
Xu L; Wu H; Jiang C; Wang H; Gao B; Yan S; Qi Y; Zhou S
Discov Med; 2016 Nov; 22(122):297-309. PubMed ID: 28009971
[TBL] [Abstract][Full Text] [Related]
38. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
39. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling.
Yue Y; Qian W; Li J; Wu S; Zhang M; Wu Z; Ma Q; Wang Z
Cancer Lett; 2020 Feb; 471():135-146. PubMed ID: 31811906
[TBL] [Abstract][Full Text] [Related]
40. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling.
Duan W; Qian W; Zhou C; Cao J; Qin T; Xiao Y; Cheng L; Li J; Chen K; Li X; Ma J; Ma Q
Oncol Rep; 2018 Sep; 40(3):1495-1502. PubMed ID: 29956804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
